Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis
Go back to Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis| GALMED PHARMACEUTIC (NASDAQ: GLMD) | Delayed: 0.56 -0.02 (3.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.58 | 52 Week High | $9.70 | |||
| Open | $0.55 | 52 Week Low | $2.78 | |||
| Day High | $0.61 | P/E | N/A | |||
| Day Low | $0.53 | EPS | $0.00 | |||
| Volume | 755,194 | |||||
